Publication - Prof. Jacob Schachter

1. Weinberger, O. Sperling, J. Schachter, U.A. Liberman, J. Pinkhas, A. DeVries. Urolithiasis associated with hypercalciuria. Int. Urol. Nephrol., 9:213, 1977.

2. Weinberger, J. Schachter, O. Sperling, U.A. Liberman, J. Pinkhas. Treatment with orthophosphosphate and hydrochlorothiazide for urolithiasis and idiopathic hypercalciuria.Urologia, 44:1, 1977.

3. Weinberger, J. Schachter, J. Pinkhas O. Sperling, Hereditary Hypercalciuric Urolithiasis. Brit. J. Urol, 53:285.1981.

4. Weinberger, J. Schachter, J. Pinkhas, O. Sperling. Metabolic and genetic aspects of idiopathic hypercalciuric urolothiasis. In: A. Weinberger, J. Schachter, J. Pinkhas O. Sperling, Vahlensieck (ed.) Advances in Urology and Nephrology. P.57, 1981.

5. J. Barzilay, J. Schachter, E. Rakovsky, C. Mor. Coetaneous malignant lymphoma. Eur. J. Surg. Oncol., 11:337, 1985.

6. Adler, G. Gilon, H. Luria, J. Schachter, A Shani, C. Servadio, J. Stein. Active specific immunotherapy of renal carcinoma patients. J. Biol. Res. Modif., 6:610, 1987.

7. S. Aamdal, I. Wolff, S. Kaplan, R. Paridaens, J. Kerger, J. Schachter, J. Wanders, H.R Franklin, J. Verweij. Docetaxel in advanced malignant melanoma: a phase 2 study of the EORTC early clinical trials group. Eur. J. Cancer, 30/8:1061, 1994.

8. Sulkes, U. Beller, T. Peretz, J. Schachter, C. McDaniel, B. Winograd. Taxol: Initial Israeli experience with a novel anticancer agent. Isr. J. Med Sci., 30:70-78, 1994.

9. Adler, J. Schachter, Y. Barenholz, L.K. Bar, T. Klein, A. Sulkes, R. Michowiz, Y. Cohen, I. Kedar. Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients: Clinical and immunobiological effects. Cancer biother, 10(4):293-306, 1995.

10. Milo, G. Tamir, J. Sulkes, J. Schachter, D. Hauben. Epidemiology and prognostic factors in coetaneous malignant melanoma. Harefuah, 128:12, 1995 (Hebrew).

11. Klein, I. Levin, J. Schachter, H. Lurie, T. Klein, A. Siegel. The expression of CA-15-3 on breast cancer tumor cells in the serum in relation to survival.Cell Vision, 2:455-457, 1995.

12. T. Klein, I. Levin, A. Niska, R. Koren, R. Gal, J. Schachter, R. Narinski, B. Klein. Correlation between tumor and serum ß2m, expression in patients with breast cancer. Eur. J. Immunogenet., 23:417-423, 1996.

13. J. Schachter, T. Klein, B. Klein, A. Adler. HLA class I and advanced melanoma in Israel Jews. Int. J. Oncol., 10(3):645-648, 1997.

14. J. Schachter, E. Rakowsky, A. Sulkes, A. Adler. Sequential four drug chemotherapy program and biotherapy with interferon alpha and GM-CSF. Cancer Biother. Radiopharma., 13:155-164, 1998.

15. M. Mishaeli, B. Klein, E. Sadikov, I. Bayer, R. Koren, R. Gal, E. Rakowsky, I. Levin, B. Kfir,J. Schachter. Initial TPS serum level as an indicator of relapse and survival in colorectal cancer.Anticancer Res., 18:2101-2106, 1998.

16. E. Fenig, E. Eidelevich, E. Njugona, A. Katz, H. Gutman, A. Sulkes, J. Schachter. The role of radiation therapy in the management of coetaneous malignant melanoma. Am. J. Clin. Oncol., 22(2):184-186, 1999.

17. J. Schachter, B. Brenner, E. Fenig, J. Yahav, G. Marshak, A. Sulkes, H. Gutman. Toxicity of Adjuvant High Dose Interferon-α-2b in Patients with Coetaneous Melanoma at high risk of Recurrence. Oncology Rep, 6(6):1389-1393, 1999.

18. Brenner, E. Rakowsky, A. Katz, H. Gutman, A. Sulkes, J. Schachter, E. Fenig. Tailoring Treatment for Classical Kaposi Sarcoma: Comprehensive Clinical Guidelines. Int. J. Oncol., 14:1097-1102, 1999.

19. J. Schachter, A.L. Vaturi S. Mekhmandarov, M. Feinmesser, F. Fening, G. Tamir, H. Gutman. Standard and nonstandard applications of sentinel node guided melanoma Surgery.World J. Surg.,24:491-495, 2000.

20. N. Wasserberg, J. Schachter, E. Fening, M. Feinmesser, H. Gutman. Merkel Cell Carcinoma, a Plea for Application of the Sentinel Node Technique. Dermatologic Surgery, 26:138-141, 2000.

21. R. Paridaens, L. Biganzoli, P. Bruning, J.G.M Klijn. T. Gamucci, S. Houston, R. Coleman, J. Schachter, A. Van Vreckem, R. Sylvester, A. Awada, J. Wildiers, M. Piccart. Taxol Versus Doxorubicin as First-Line Single Agent Chemotherapy for Metastatic Breast Cancer - An EORTC Randomized Study with Crossover. J. Clin. Oncol, 18: 724-733, 2000.

22. Fenig, B. Brener, E. Njuguna, A. Katz, J. Schachter, A. Sulkes. Oral etoposide for Merkel cell carcinoma in patients previously treated with intravenous Etoposide. Am. J. Clin. Oncol. 23(1):65-67, 2000.

23. Fenig, B. Brenner, A. Katz, J. Sulkes, M. Lapidot, J. Schachter, H. Melik, A. Sulkes, H. Gutman. Topical Biafine and Lipiderm for the prevention of radiation dermatitis: A randomized prospective trial. Oncology Rep. 8: 305-309, 2001.

24. H. Gutman, J. Schachter, E. Stopel, R. Gutmen, J. Lahav. Impaired platelet aggregation in melanoma patients treated with Interferon-α-2b adjuvant therapy. Cancer. 94: 780-785, 2002.

25. M. Feinmesser, J. Schachter, A. Tobar, J. Sulkes, H. Gutman, N. Kruk, E. Okon. Relations of tumorigenic malignant melanoma to dermal elastin. Am. J. Dermatopathol. 24(2): 108-117, 2002.

26. T. Waserberg, S. Morgenstern, J. Schachter, E. Fenig, S. Lelcuk, H. Gutman. Risk factors for lymph node metastases in breast ductal carcinoma in situ with minimal invasive component.Arch Surg. 137: 1249-1252, 2002.

27. J. Schachter, B. Brenner, E. Fenig, R. Gutman, A. Sulkes, H. Gutman. Patterns of failure in patients with malignant melanoma treated with high dose Interferon-α-2b in the adjustment setting. Melanoma Res. 13: 93-96, 2003.

28. Brenner, S. Borok, E. Rakowsky, E. Fenig, H. Gutman, J. Sulkes, A. Sulkes, J. Schachter. Older age and second skin cancer as prognostic factors in localized malignant Melanoma.Oncology Rep. 10(6) :2051-2057, 2003.

29. Brenner, L. Wasserman, E. Beery, J. Nordenberg, J. Schachter, H. Gutman, E. Fenig. Variable cytotoxicity of amifostine in malignant and non-malignant cell lines. Oncology Rep. 10: 1609-1613, 2003.

30. H. Gutman, J. Schachter, N. Wasserberg, I. Shechtman, F. Greiff. Are solitary breast papilomas entirely benign? Archive Surg. 138:1330-1333, 2003.

31. T. Menes, J. Schachter, S. Morgenstern, E. Fenig, H. Lurie, H. Gutman. Primary Squamous Cell Carcinoma (SqCC) of the Breast. Am. J. Clin. Oncol. 26:571-573, 2003.

32. N. Wasserberg, H. Tulchinsky, J. Schachter, M. Feinmesser, H. Gutman.Sentinel-lymph-node biopsy (SLNB) for melanoma is complication-free.Euro J Surg Oncol. 30:851-856, 2004.

33. T. Shpitzer, K. Segal, J. Schachter, R. Hardoff, D. Guttman, D. Ulanovski, R. Feinmesser, H. Gutman. Sentinel node guided surgery for melanoma in the head and neck region. Melanoma Res. 14: 283-287, 2004.

34. T.S. Mennes, J. Schachter, A.P. Seinmetz, R. Hardoff, H. Gutman. Lymphatic Drainage to the Popliteal Basin in Distal Lower Extremity Malignant Melanoma.Arch Surg. 139: 1002-1006, 2004.

35. Marshak, E. Rakowsky, J. Schachter, J. Shvero, R. Feinmesser, A. Sulkes, B. Brenner. Is the delay in starting postoperative radiotherapy a key factor in the outcome of advanced (T3 and T4) laryngeal cancer? Otolaryngology - Head and Neck Surgery. 131: 489-493, 2004.

36. N. Nathansohn, J. Schachter, H. Gutman. Patterns of Recurrence in Patients with Melanoma after Radical Lymph Node Dissection. Arch Surg. 140:1172-1177, 2005.

37. M.J. Besser, A.J. Treves, O. Itzhaki, I. Hardan, A. Nagler, M.Z. Papa, R. Catane, E. Winkler, B. Shalom-Zifroni, J. Schachter. Adoptive Cell Therapy for Metastatic Melanoma Patients Pre-clinical development at the Sheba Medical Center. IMAJ 8:1-5, 2006

38. G Markel, R. Seidman, N. Stern, T. Cohen-Sinai, O. Izhaki, G. Katz, M. Besser, AJ.Treves, RS.Blumberg, R. Loewenthal, O. Mandelboim, A. Orenstein, and J. Schachter. Inhibition of Human Tumor-Infiltrating Lymphocyte Effector Functions by. J Immunol.; 177: 6062-6071, 2006

39. Y. Hamama,Raz, Z. Solomon, J. Schachter, E. Azizi. Objective and subjective stressors and the psychological adjustment of melanoma survivors. Accepted for publication. Psychooncology. 2007 Apr;16(4):287-94

40. J .Schachter, U Katz, A Mahrer, D Barak, LZ David, J Nusbacher, Y Shoenfeld.Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma. Ann N Y Acad Sci. 2007 Sep;1110:305-14.

41. N Nathansohn, A Orenstein, H Trau, A Liran, J Schachter. Pigmented lesions clinic for early detection of melanoma: preliminary results. Isr Med Assoc J. 2007 Oct;9(10):708-12.

42. GI Keshet, I Goldstein, O Itzhaki, K Cesarkas, L Shenhav, A Yakirevitch, AJ Treves, JSchachter, N Amariglio, G Rechavi. MDR1 Expression Identifies Human Melanoma Stem Cells.Biochem Biophys Res Commun. 2008 Apr 18;368(4):930-6
(IF - 2.749 Biophysics 27/69)

43. E Schallmach, R Sareli, MJ Besser, S Leipsiger, I Hardan, AJ Treves, A Nagler, J Schachter. Collection of Large-Scale Expanded Lymphocyte Cultures for Adoptive Immunotherapy Using a COBE Spectra Apheresis Machine. J Immunother. 2008 Jul-Aug;31(6):563-8 
( IF-4.873 Medicine, Research & Experimental 8/81 )

44. E Soudry, H. Gutman, M Feinmesser, R Gutman, J Schachter. "Gloves-And-Socks" Melanoma: Does Histology Make a Difference? Dermatol Surg. 2008 Oct;34(10):1372-8. 
(IF- 1.769 Surgery 45/139)

45. J Bar, R Yerushalmi, R Shapira-Frummer, I Kutchuk, A Sulkes, H Gutman, R Catane, J Schachter. Concurrent Chemobiotherapy with Cisplatin, Dacarbazine, Decrescendo Interleukin-2 And Interferon Alpha2b In Patients with Metastatic Melanoma. Oncol Rep. 2008 Dec;20(6):1533-8. 
(IF-1.597 Oncology 97/132)

46. G Markel, T Cohen-Sinai, MJ Besser, K Oved, O Itzhaki, R Seidman, E Fridman, AJ Treves, Y Keisari, Z Dotan, J Ramon, J Schachter. Preclinical Evaluation of Adoptive Cell Therapy for Patients with Metastatic Renal Cell Carcinoma. Anticancer Res. 2009 Jan;29(1):145-54. 
(IF-1.597 Oncology 108/132)

47. G Markel, R Seidman, Y Cohen, MJ Besser, TC Sinai, AJ Treves, A Orenstein, R Berger, J Schachter. Dynamic Expression of Protective CEACAM1 on Melanoma Cells During Specific Immune Attack. Immunology. 2009 Feb;126(2):186-200. 
(IF-3.398 Immunology 38/119)

48. M.J. Besser, E. Schallmach, K. Oved, A.J. Treves, G. Markel, Y. Reiter, J. Schachter. Modifying IL-2 Concentrations During Culture Improves Function Of T-Cells For Adoptive Immunotherapy. Cytotherapy. 2009;11(2):206-17 
(IF-3.553 Biotechnology & Applied Microbiology 26/138)

49. MJ Besser, R Shapira-Frommer, AJ Treves, D Zippel, O Itzhaki, E Schallmach, A Kubi, B Shalmon, I Hardan, R Catane, E Segal, G Markel, S Apter, AB Nun, I Kuchuk, A Shimoni, A Nagler, J Schachter. Minimally Cultured Or Selected Autologous Tumor-Infiltrating Lymphocytes After A Lympho-Depleting Chemotherapy Regimen In Metastatic Melanoma Patients. J Immunother. 2009 May;32(4):415-23. 
(IF-4.873 Immunology 17/119)

50. J Mashiah, S Brenner, K Pessach, V Barak, J Schachter. Differences In Cytokine Levels In Melanoma Patients With And Without Redness (Brenner Sign) Anticancer Res. 2009 May;29(5):1793-6.
(IF-1.597 Oncology 108/132)

51. K Oved, E Eden, M Akerman, R Noy, R Wolchinski, O Izhaki, E Schalmmach, A Kubi, N Zabari, J Schachter, U Alon, Y Mandel- Gutfreud, MJ Besser, Y Reitr. Predicting and Controlling the Reactivity of Immune Cell Populations Against Cancer. Mol Syst Biol. 2009;5:265:1-11.
(IF 9.954 Biochemistry & Molecular Biology 16/263) 
This Article Was Selected Editor's Choice At Science 8 May 2009: 693

52. G. Markel, R Seidman, MJ Besser, N Zabari, R Ortenberg, R Shapira, AJ Treves, R Loewenthal, A Orenstein, A Nagler, J Schachter. Natural Killer Lysis Receptor (NKLR)/NKLR-Ligand Matching as a Novel Approach for Enhancing Anti-Tumor Activity of Allogeneic NK Cells.PLoS ONE. 2009;4(5):e5597 (not ranked yet)

53. I Gluck, AJ Simon, R Catane, R Pfeffer, J Schachter, G Rechavi, J Bar, Germline analysis of Thymidine/Guanidine polymorphism at position 309 of the Mdm2 promoter in malignant melanoma patients. Melanoma Research. 2009 Aug;19(4):199-202.
(IF-2.225 Dermatology 10/41)

54. DB Zippel, R Shapira, I Kuchuk, D Goiten, A Winkler, MZ Papa, J Schachter. Outcome of thick, node negative melanomas. IMAJ. 2009 November;9:669-672.
(IF -0.577 Medicine, General & Internal 75/100)

55. Markel G. Bar J. Seidman R. Sapoznik S.Ortenberg R. Besser MJ. Shapira R. Kubi A. Nardini G. Tissone A. Treves AJ. Winkler E. Orenstein A.
Schachter J. Systemic dysregulation of CEACAM1 in melanoma patients. 2009. Cancer Immunol. Immunother. 2010;59:215-230.
(IF-3.728 Immunology 33/119)

56. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A and Schachter J. Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-Term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. Clin Cancer Res .2010:16[9]:2646-2655.

(Oncology 14/141, IF 6.646) 

57.     Greenberg E, Hershkovitz L, Itzhaki O, Hajdu S,Nemlich Y, Ortenberg R, Gefen N, Edry L, Modai S, Keisari Y, Besser MJ, Schachter J, Shomron N, Markel G. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 6(4):e18936, 2011.

58.     Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, Hershkovitz L, Traves AJ, Shalmon B, Zippel D, Markel D, Shapira-Formmer R, Shachter J, Besser MJ. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother 34(2):212-220, 2011.

59.     Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, Gefen N, Edry L,     Modai S, Keisary Y, Besser MJ, Schachter J, Shomron N, Markel G. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 6(4):e18936, 2011.

60.     Greenberg E, Rechavi G, Amariglio N, Solomon O, Schachter J, Markel G, Eyal E. Mutagen-specific mutation signature determines global microRNA binding. PLoS One6(11):e27400, 2011.

61.     Greenberg E. Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, gefen N, Edry L, Modai S, Keisari Y, Besser MJ, Schachter J, Shomron N. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 6(4):e18936, 2011.

62.     Sappoznik S, Faranesh S, Ortenberg R, Hamburger T, Barak V, Peretz T, Schachter J, Markel G, Lotem M. Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients. Clin Dev Immunol 2011, in press.

63.     Khatib N, Pe'er J, Ortenberg R, Schachter J, Frenkel S, Markel G, Amer R. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: Correlation with clinical and histological survival markers. Invest Opthal Vis Sci 52(13):9368-9372, 2011.

64.     Greenberg E, Rechavi G, Amariglio N, Solomon O, Schachter J, Markel G, Eyal E. Mutagen-speciric mutation signature determines global microRNA binding. PLoS One6(11):e27400, 2011.

65.     Sapoznik S, Ortenberg R, Schachter J, Markel G. CEACAM1 in malignant melanoma: A diagnostic and therapeutic target. Curr Top Med Chem 12(1):3-10, 2012.